Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma

Journal of Virology

Volumn 85, Issue 11, 2011, Pages 5581-5592

  Lee, Sang Hyun ^a,b   Jia, Shidong ^a,b   Zhu, Yanni ^c   Utermark, Tamara ^a,b   Signoretti, Sabina ^a,b   Loda, Massimo ^a,b   Schaffhausen, Brian ^c   Roberts, Thomas M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; GENOTYPE; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMID; POLYOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; STROMA; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA; GENE EXPRESSION PROFILING; MALE; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; POLYOMAVIRUS; PROSTATIC NEOPLASMS; VIRULENCE FACTORS;

ANIMALIA; MAMMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS MUSCULUS; POLYOMAVIRUS;

EID: 79956094293     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02609-10     Document Type: Article

References (73)

1. Abate-Shen, C., et al. 2003. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 63:3886-3890.
2. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4:540-550.
3. Begley, L. A., et al. 2008. CXCL5 promotes prostate cancer progression. Neoplasia 10:244-254.
4. Bierie, B., et al. 2008. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 68:1809-1819.
5. Campbell, K. S., et al. 1994. Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 91:6344-6348.
6. Casimiro, M., et al. 2007. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 67:4364-4372.
7. Cecena, G., F. Wen, R. D. Cardiff, and R. G. Oshima. 2006. Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene. Am. J. Pathol. 168:310-320.
8. Chan, J. M., et al. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566.
9. Chen, Z., et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730.
10. Di Cristofano, A., M. De Acetis, A. Koff, C. Cordon-Cardo, and P. P. Pandolfi. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:222-224.
11. Di Cristofano, A., B. Pesce, C. Cordon-Cardo, and P. P. Pandolfi. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:348-355.
12. Dilworth, S. M., et al. 1994. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature 367: 87-90.
13. Efron, B., R. Tisbshirani, J. D. Storey, and V. Tusher. 2001. Empirical Bayes analysis of a microarray experiment. J. Am. Stat. Assoc. 96:1151-1160.
14. Ellwood-Yen, K., et al. 2003. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238.
15. Elo, T. D., et al. 2010. Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia 12:915-927.
16. Erez, N., M. Truitt, P. Olson, S. T. Arron, and D. Hanahan. 2010. Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17:135-147.
17. Fluck, M. M., and B. S. Schaffhausen. 2009. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 73:542-563.
18. Fossa, A., et al. 2002. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int. J. Cancer 99:100-105.
19. Freund, R., C. J. Dawe, J. P. Carroll, and T. L. Benjamin. 1992. Changes in frequency, morphology, and behavior of tumors induced in mice by a polyoma virus mutant with a specifically altered oncogene. Am. J. Pathol. 141: 1409-1425.
20. Glinsky, G. V., A. B. Glinskii, A. J. Stephenson, R. M. Hoffman, and W. L. Gerald. 2004. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113:913-923.
21. Gottlieb, K. A., and L. P. Villarreal. 2001. Natural biology of polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 65:288-318.
22. Greenberg, N. M., et al. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92:3439-3443.
23. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961.
24. Hahn, W. C., and R. A. Weinberg. 2002. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:331-341.
25. Haram, K. M., et al. 2008. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 68:1517-1530.
26. Herschkowitz, J. I., et al. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8:R76.
27. Jia, S., et al. 2008. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776-779.
28. Kalluri, R., and M. Zeisberg. 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6:392-401.
29. Kaplan, D. R., et al. 1986. Phosphatidylinositol metabolism and polyomamediated transformation. Proc. Natl. Acad. Sci. U. S. A. 83:3624-3628.
30. Kim, M. J., et al. 2002. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62:2999-3004.
31. Kim, M. J., et al. 2002. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:2884-2889.
32. Lee, S. H., et al. 2010. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc. Natl. Acad. Sci. U. S. A. 107:11002-11007.
33. Lewis, B. C., D. S. Klimstra, and H. E. Varmus. 2003. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes Dev. 17:3127-3138.
34. Li, Z., M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis. 2006. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 27:1054-1067.
35. Lin, E. Y., A. V. Nguyen, R. G. Russell, and J. W. Pollard. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727-740.
36. Lu, Y., et al. 2008. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol. Cancer Res. 6:546-554.
37. Ma, X., et al. 2005. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res. 65:5730-5739.
38. Maglione, J. E., et al. 2004. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol. Cancer Ther. 3:941-953.
39. Majumder, P. K., et al. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10:594-601.
40. Majumder, P. K., et al. 2003. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. U. S. A. 100:7841-7846.
41. Masumori, N., et al. 2001. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61:2239-2249.
42. Myers, R. B., S. Srivastava, D. K. Oelschlager, and W. E. Grizzle. 1994. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86:1140-1145.
43. Namba, R., et al. 2006. Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 6:275.
44. Osman, I., et al. 2005. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J. Urol. 174:2174-2177.
45. Ouyang, X., et al. 2008. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68: 2132-2144.
46. Pawitan, Y., et al. 2005. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two populationbased cohorts. Breast Cancer Res. 7:R953-R964.
47. Pedersen, T. X., et al. 2005. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 26:1233-1240.
48. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
49. Qiu, T. H., et al. 2004. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res. 64:5973-5981.
50. Schaefer, C., G. D. Friedman, and J. C. P. Quesenberry. 1998. IGF-1 and prostate cancer. Science 282:199a.
51. Schaffhausen, B. S., and T. M. Roberts. 2009. Lessons from polyoma middle T antigen on signaling and transformation: a DNA tumor virus contribution to the war on cancer. Virology 384:304-316.
52. Scherl, A., J. F. Li, R. D. Cardiff, and N. Schreiber-Agus. 2004. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 59:448-459.
53. Shepard, C. R., J. Kassis, D. L. Whaley, H. G. Kim, and A. Wells. 2007. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26:3020-3026.
54. Signoretti, S., et al. 2000. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92:1918-1925.
55. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl. Genet. Mol. Biol. 3:Article3.
56. Song, Z., et al. 2002. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 62:5096-5105.
57. Srinivas, S., A. Schonthal, and W. Eckhart. 1994. Polyomavirus middle-sized tumor antigen modulates c-Jun phosphorylation and transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 91:10064-10068.
58. Su, W., W. Liu, B. S. Schaffhausen, and T. M. Roberts. 1995. Association of polyomavirus middle tumor antigen with phospholipase C-gamma 1. J. Biol. Chem. 270:12331-12334.
59. Subramanian, A., et al. 2005. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545-15550.
60. Sung, S. Y., et al. 2008. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 68:9996-10003.
61. Suzuki, H., et al. 1998. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58: 204-209.
62. Tehranian, A., et al. 1996. Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. Am. J. Pathol. 149:1177-1191.
63. Trotman, L. C., et al. 2003. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1:E59.
64. Tuxhorn, J. A., G. E. Ayala, and D. R. Rowley. 2001. Reactive stroma in prostate cancer progression. J. Urol. 166:2472-2483.
65. Utermark, T., B. S. Schaffhausen, T. M. Roberts, and J. J. Zhao. 2007. The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J. Virol. 81:7069-7076.
66. Vindrieux, D., P. Escobar, and G. Lazennec. 2009. Emerging roles of chemokines in prostate cancer. Endocr. Relat. Cancer 16:663-673.
67. Vleugel, M. M., A. E. Greijer, R. Bos, E. van der Wall, and P. J. van Diest. 2006. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 37:668-674.
68. Wang, S., et al. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221.
69. Wang, S., et al. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U. S. A. 103:1480-1485.
70. Webster, M. A., et al. 1998. Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 18:2344-2359.
71. Whitman, M., D. R. Kaplan, B. Schaffhausen, L. Cantley, and T. M. Roberts. 1985. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315:239-242.
72. Yang, L., et al. 2008. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35.
73. Zhang, J., T. Z. Thomas, S. Kasper, and R. J. Matusik. 2000. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710.